Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma, Inc. (Nasdaq: SILO) regularly issues news updates that reflect its dual identity as a developmental-stage biopharmaceutical company and a cryptocurrency treasury company. Its press releases highlight progress in drug development for stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, alongside announcements about its evolving digital assets treasury strategy.
On the biopharmaceutical side, Silo’s news flow centers on SPC-15, an investigational intranasal serotonin 5-HT4 receptor agonist being developed for PTSD and stress-induced anxiety. Recent releases describe IND-enabling toxicology and toxicokinetic work, large animal safety studies, drug-device evaluations of a soft mist nasal spray system, and plans for Phase 1 single ascending dose and multiple ascending dose studies. The company also reports on regulatory strategy, including its intention to pursue the FDA’s 505(b)(2) pathway, and on collaborations with organizations such as Allucent and Columbia University.
News items also cover Silo’s broader pipeline, including SP-26 for fibromyalgia and chronic pain and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Investors following SILO news can expect updates on preclinical data, clinical trial preparations, intellectual property expansion, and strategic academic and CRO partnerships.
In parallel, Silo’s releases describe the launch and build-out of its digital assets treasury. Announcements detail initial purchases of Bitcoin, Ethereum, Solana, and ResearchCoin, the establishment of a Crypto Advisory Board, engagement of Fireblocks for institutional-grade custody and infrastructure, and allocation to the Alphaledger T12 Fund for tokenized real-world asset exposure on the Solana blockchain. Additional disclosures include software and domain acquisitions related to crypto applications and updates on treasury diversification objectives.
Visitors to the SILO news page can use this stream of company-issued information to track clinical milestones, regulatory steps, capital markets activity, and digital asset strategy developments over time.
Silo Pharma has entered an exclusive option agreement with the University of Maryland to investigate novel joint-homing peptides aimed at treating inflammation related to autoimmune diseases, specifically rheumatoid arthritis. These peptides could enhance drug delivery directly to affected joints, potentially increasing therapeutic efficacy while minimizing systemic toxicity. Silo's CEO emphasized the potential of this technology as a revolutionary drug delivery platform that meets the need for innovative treatments for patients with rare diseases.
Silo Pharma, a biopharmaceutical company, announced that CEO Eric Weisblum will present at Proactive's One2One Virtual Investor Forum on February 23, 2021, at 1 p.m. EST. The event is expected to reach Proactive's 20,000 YouTube subscribers and will be broadcasted globally. Silo Pharma focuses on merging traditional therapeutics with psychedelic research to address conditions such as depression, PTSD, and Parkinson's disease. The presentation will include a Q&A session and will be made available online after the event.
Silo Pharma has signed a Master License Agreement with the University of Maryland Baltimore to license innovative Central nervous system-homing peptides aimed at treating multiple sclerosis and other neuroinflammatory disorders. This agreement follows preclinical studies that support the peptide's efficacy. CEO Eric Weisblum emphasized Silo's commitment to merging traditional therapeutics with psychedelic research, suggesting potential benefits for patients with neurological conditions.
Silo Pharma, a developmental stage biopharmaceutical company, has secured $4.275 million through Securities Purchase Agreements for its Series C Preferred Stock. The financing involves issuing 4,276 shares and warrants for 14,253,333 shares of common stock with an exercise price of $0.30 per share. The funds will support the development of psychedelic therapeutics for conditions like depression and PTSD. The transaction, expected to close by February 11, 2021, reflects investor confidence in Silo's strategic growth plan.